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 2 
What is the key question? Does the development of a postoperative pulmonary 22 
complication (PPC) following thoracic surgery for lung resection impact on long-term 23 
survival? 24 
What is the bottom line? After excluding immediate post-operative deaths, 25 
developing a PPC is a significant independent risk factor for late deaths and these 26 
patients have a worse long-term survival.   27 
Why read on? We demonstrate in our large prospective cohort that PPCs are 28 
common following thoracic surgery, both the short and long-term effects of 29 
developing a PPC are striking; COPD and smoking are significant independent risk 30 
factors.  31 
 32 
ABSTRACT 33 
Introduction Postoperative pulmonary complications (PPC) such as atelectasis and 34 
pneumonia are common following lung resection. PPCs have a significant clinical 35 
impact on postoperative morbidity and mortality. We studied the long-term effects 36 
of PPCs and sought to identify independent risk factors. 37 
Methods A prospective observational study involved all patients following lung 38 
resection in a regional thoracic centre over 4 years. PPCs were assessed daily in 39 
hospital using the Melbourne group scale based on chest x-ray, white cell count, 40 
fever, purulent sputum, microbiology, oxygen saturations, physician diagnosis and 41 
intensive therapy unit (ITU)/high dependency unit readmission. Follow up included 42 
hospital length of stay (LOS), 30-day readmissions, and mortality. 43 
 3 
Results 86 of 670 patients (13%) who underwent a lung resection developed a PPC. 44 
Those patients had a significantly longer hospital LOS in days (13, 95%CI 10.5-14.9 vs. 45 
6.3, 95%CI 5.9-6.7; p<0.001) and higher rates of both ITU admissions (28% vs. 1.9%; 46 
p<0.001) and 30-day hospital readmissions (20.7% vs. 11.9%; p<0.05). Significant 47 
independent risk factors for development of PPC were COPD and smoking (p<0.05), 48 
not age. Excluding early postoperative deaths, developing a PPC resulted a 49 
significantly reduced overall survival in months (40 95%CI 34-44 vs. 46 95%CI 44-47; 50 
p=0.006). Developing a PPC is associated with a higher non-cancer related late 51 
deaths (11 vs. 5%; p=0.020). PPC is a significant independent risk factor for late 52 
deaths in non-small cell lung cancer patients (HR 2.0, 95%CI 1.9-3.2; p=0.006). 53 
Conclusion Developing a PPC after thoracic surgery is common and is associated 54 
with a poorer long-term outcome.  55 
 56 
BACKGROUND 57 
Lung cancer is the most common cause of cancer death within the UK [1]. For those 58 
patients diagnosed with non-small cell lung cancer (NSCLC) potentially curative 59 
surgery is generally accepted as the most effective treatment [2]. There is some 60 
evidence that patients with lung cancer in the UK present at a later stage and have a 61 
higher comorbidity than patients in some other European countries [3]. Thus, 62 
surgical resection rates amongst those with proven NSCLC are lower in the UK (14%) 63 
compared to central Europe (24%) [4, 5]. To address this most recent European and 64 
UK guidelines has widened the selection criteria for lung cancer surgery [6], which 65 
 4 
has helped improve resection rates. The 5-year survival rates for lung cancer in the 66 
UK is poor (9%) compared to central Europe (13%) as demonstrated in the 1999-67 
2007 EUROCARE-5 report [7]. A more recent study has shown that cancer survival in 68 
England is improving, however continued investment is needed to close this 69 
international gap [8]. Furthermore, whilst in hospital mortality has fallen over the 70 
last 3 decades, mortality rates within the first 90 days of surgery are considerable 71 
[9]. We need to understand the causes of these late complications if we are to 72 
improve long-term outcomes.  73 
Lung cancer resection is also associated with a considerable risk of postoperative 74 
pulmonary complications (PPCs), of which pneumonia and atelectasis are the most 75 
common [10]. PPCs have a significant health and economic impact on patients and 76 
health care services. Indeed, as less fit patients are undergoing surgery, the 77 
incidence of PPCs is likely to increase further. The longer-term effects of developing 78 
a PPC in hospital following lung cancer surgery have not been defined. The 79 
identification of modifiable risk factors for PPCs has a crucial role in the development 80 
of innovative strategies to reduce the impact and incidence of PPCs. We hypothesise 81 
that PPCs are associated with the late postoperative mortality and morbidity 82 
observed following lung resection. 83 
This study aims to assess both immediate and long-term impact of PPCs, and to 84 
identify potentially modifiable independent risk factors. 85 
 86 
METHODS 87 
 5 
This prospective observational study was conducted at a single centre large regional 88 
thoracic unit serving 6 million people.  Consecutive patients who underwent open 89 
thoracotomy or video-assisted thoracoscopic surgery (VATS) for lung 90 
resection/removal in a regional thoracic centre between April 2010 and April 2014 91 
were observed. This study was conducted with the approval of the National 92 
Research Ethics Service (NRES) Committee West Midlands. This study was registered 93 
with the Birmingham Heartlands Hospital audit department (audit code 1672). 94 
Decisions regarding patient operability and resectability were informed by the British 95 
Thoracic Society guidelines for lung cancer resection [6]. 96 
Patients were admitted to hospital on the day of surgery. All operations were 97 
performed with single lung ventilation under general anaesthesia, and patients were 98 
subsequently scheduled for extubation in the operating room. Postoperatively, 99 
patients were managed in a dedicated thoracic high dependency unit HDU (level 2) 100 
and ward unless complications required their admission to the ITU. Postoperative 101 
pain control was achieved by continuous thoracic epidural analgesia, paravertebral 102 
infusion, intrathecal morphine and/or intercostal blocks or systemic opioids 103 
(parenteral administration or intravenous patient-controlled administration). The 104 
choice of analgesic technique was made by the anaesthetist after discussion with the 105 
patient. From the first postoperative day, all patients had a daily physiotherapy 106 
programme comprising deep breathing exercises, incentive spirometry, supported 107 
coughing and mobilisation. 108 
The Melbourne Group Scale (MGS) is a standardised scoring system validated by our 109 
group to define the presence of a PPC such as pneumonia or clinically significant 110 
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atelectasis, which are likely to adversely affect the patient’s clinical course [10-11]. 111 
Using this score, PPC is defined in those patients presenting with four or more of the 112 
following eight dichotomous factors: chest x-ray (CXR) findings of atelectasis or 113 
consolidation; raised white cell count (WCC) (>11.2x10
9
/l); temperature >38°C; signs 114 
of infection on sputum microbiology; purulent sputum differing from preoperative 115 
status; oxygen saturations <90% on room air; physician diagnosis of pneumonia; and 116 
prolonged HDU stay or readmission to HDU or ITU for respiratory complications. The 117 
MGS was used daily by senior physiotherapists who were performing their routine 118 
respiratory assessments. The discharge criteria, agreed with investigators in advance 119 
included patients who were medically fit and who had been discharged from 120 
physiotherapy. 121 
Data collected included demographics and pre-operative record of smoking status, 122 
body mass index (BMI), percentage predicted forced expiratory volume in one 123 
second (FEV1), American Society of Anesthetist (ASA) score, subjective preoperative 124 
activity level and comorbidities including chronic obstructive pulmonary disease 125 
(COPD) defined by clinical diagnosis of the referring clinician and staged according to 126 
percentage predicted FEV1. Postoperative data included type of analgesia used and 127 
underlying pathology (including lung cancer staging if applicable). Total length of 128 
stay (LOS) was defined as the LOS in hospital after the date of surgery. The HDU and 129 
ITU LOS were also recorded, as well as ITU admission and 30-day readmission to 130 
hospital secondary to surgical or pulmonary complications. All patients were 131 
followed up for overall survival (OS) and the cause of death was obtained from both 132 
the death certificate and hospital records. Deaths were classified as postoperative 133 
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complication for patients who died within initial hospital admission or within 30 days 134 
of surgery, cancer related for those patients who died of disease 135 
progression/recurrence, and non-cancer related, or cause of death uncertain where 136 
records were not available or unclear. 137 
Statistical analysis 138 
Results are expressed as mean (SD or 95% CI) for continuous variables and as a 139 
percentage for categorical variables. Univariate analysis of risk factors for 140 
development of PPC were assessed by performing individual un-adjusted logistic 141 
regression analysis, inclusion of one covariate at a time. Risk ratios with 95%CI were 142 
generated for variables found to have statistically significant association with PPC on 143 
univariate analysis. A backward multivariate binary logistic regression analysis was 144 
performed to identify the independent predictors of PPC within this dataset.  145 
The effect of PPC on hospital, HDU and ITU LOS were assessed using the Mann-146 
Whitney non-parametric test to accommodate for the presence of positive 147 
skewness. Kaplan Meyer plots and the log-rank test were used to assess the impact 148 
of PPC on survival. Cox regression was assessed including all risk factors in a model 149 
for long-term survival. All analyses were performed using the IBM SPSS version 20 150 
and SAS 9.3 statistical package version (SAS Institue, Inc, Carry NC). 151 
 152 
RESULTS 153 
There were 670 patients who underwent pulmonary resections during the study 154 
period; 377 of who were male (56%). The mean±SD age of the group was 66.4±10.8 155 
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years. Mean predicted FEV1 was 80.2±20.8%, mean BMI 26.9±8.1 kg/m2, 328 156 
patients (49%) had an ASA score ≥3, 176 patients (26%) had COPD, 149 patients 157 
(22%) were current smokers.  158 
The most frequent procedure was lobectomy (n=497, 74%) followed by wedge or 159 
segmentectomy (n=111, 16%) and pneumonectomy (n=37, 5.5%). VATS lobectomy 160 
and segmentectomy were also performed (n=54, 8% and n=8, 1% respectively).  161 
Most common histological diagnosis was NSCLC (n=477, 71.2%) followed by benign 162 
disease (n=73, 11%) and metastatic disease of non-lung primary (n=69, 10.3%). 163 
Eighty-eight patients (13%) had clinical evidence of PPC using the MGS. The median 164 
day of this occurring was day 2 postoperative. The four most common positive 165 
factors to trigger a score of 4 were raised WCC (n=75, 85%), purulent sputum (n=72, 166 
82%), CXR findings (n=69, 78%) and reduced saturations (n=68, 77%). 167 
On univariate analysis (table 1) the significant risk factors associated with developing 168 
a PPC were percentage predicted FEV1, ASA >3 (Risk Ratio [RR] [4 vs. 1] 4.11, 95%CI 169 
1.53-11), self-reported preoperative activity level ≤400m (RR 1.8, 95%CI 1.20-1.68), 170 
COPD diagnosis (RR 2.13, 95%CI 2.45-15.01) and current smoking (RR [current vs. 171 
never] 6.06, 95%CI 2.57-3.40) (p<0.05). Age, BMI, type of surgery (individually or 172 
collectively), VATS approach, cancer diagnosis or staging and cardiovascular disease 173 
was not significantly associated with development of PPC. 174 
  175 
Table 1 Baseline characteristics in PPC and non-PPC groups including univariate 176 
analysis of risk factors associated with developing PPC. 177 
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Variables 
 
Value 
 
Total 
(n=670) 
PPC  
(n=88) 
Non-PPC  
(n=582) 
P-value 
 
Age  Mean (±SD) 66.4 (±10.8) 67.1 (±9.6) 66.4 (±11) 0.547 
FEV1% predicted Mean (±SD) 80.2 (±20.8) 75.8 (±20.7) 80.94 (±20.7) 0.034 
BMI Mean (±SD) 26.9 (±8.1) 27.2 (±5.6) 26.9 (±8.4) 0.757 
Gender Male 
Female 
377 (66%) 
293 (44%) 
57 (65%) 
31 (35%) 
320 (55%) 
262 (45%) 
0.086 
ASA Score 1 
2 
3 
4 
44 (7%) 
298 (44%) 
313 (47%) 
15 (2%) 
5 (6%) 
32 (36%) 
44 (50%) 
7 (8%) 
39 (7%) 
266 (46%) 
269 (46%) 
8 (1%) 
0.004 
Pre-operative 
activity level 
≤ 400 m 
> 400 m 
185 (27%) 
465 (73%) 
35 (42%) 
49 (58%) 
150 (27%) 
416 (73%) 
0.005 
Type of surgery Lobectomy 
Subsegmentectomy/wedge 
Pneumonectomy 
Exploratory/biopsy 
Sleeve 
Chest wall 
497 (74%) 
111 (16%) 
37 (6%) 
13 (2%) 
8 (1%) 
4 (1%) 
64 (73%) 
15 (17%) 
3 (3.5%) 
3 (3.5%) 
2 (2%) 
1 (1%) 
433 (74%) 
96 (16.5%) 
34 (6%) 
10 (2%) 
6 (1%) 
3 (0.5%) 
0.651 
VATS Yes 
No 
62 (9%) 
608 (91%) 
9 (10%) 
79 (90%) 
53 (9%) 
529 (91%) 
0.735 
Analgesia Epidural 
Intrathecal morphine 
254 (38%) 
146 (22%) 
27 (31%) 
23 (26%) 
227 (39.4%) 
123 (21.4%) 
0.443 
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Morphine Infusion 
PCA 
Paraveterbral 
Other 
63 (9.5%) 
50 (7.5%) 
146 (22%) 
5 (1%) 
9 (10%) 
4 (5%) 
24 (27%) 
1 (1%) 
54 (9.3%) 
46 (8%) 
122 (21.2%) 
4 (0.7%) 
Pathology NSCLC 
Small cell LC 
Carcinoid 
Metastatic disease 
Benign 
Other 
477 (71.2%) 
10 (1.5%) 
27 (4%) 
69 (10.3%) 
73 (11%) 
14 (2%) 
64 (73%) 
3 (3%) 
4 (4.5%) 
6 (7%) 
11 (12.5%) 
0 
413 (71%) 
7 (1%) 
23 (2%) 
63 (11%) 
62 (11%) 
14 (4%) 
0.598 
NSCLC Staging 0 
IA 
IB 
IIA 
IIB 
IIIA 
IIIB 
IV 
5 (1%) 
120 (26%) 
112(24%) 
94 (20%) 
53 (11%) 
77 (16%) 
5 (1%) 
4 (1%) 
0  
13 (22%) 
10 (17%) 
14 (23.3%) 
9 (15%) 
13 (22%) 
0  
1 (1.7%) 
5 (1%) 
107 (26%) 
102 (25%) 
80 (20%) 
44 (11%) 
64 (16%) 
5 (1.3%) 
3 (0.7%) 
0.762 
COPD Yes 
No 
176 (26%) 
494 (74%) 
38 (43%) 
50 (57%) 
138 (24%) 
444 (76%) 
<0.001 
COPD Severity 
(FEV1% predicted) 
Mild (<80) 
Moderate (50-80) 
Severe (30-50) 
51 (29%) 
95 (54%) 
27 (16%) 
12 (32%) 
19 (61%) 
6 (16%) 
39 (29%) 
76 (56%) 
21 (15%) 
0.904 
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IHD Yes 
No 
85 (13%) 
585 (87%) 
15 (17%) 
73 (83%) 
70 (12%) 
512 (88%) 
0.665 
HTN Yes 
No 
279 (42%) 
391 (58%) 
37 (42%) 
51 (58%) 
242 (42%) 
340 (58%) 
0.934 
Diabetes Yes 
No 
80 (12%) 
590 (88%) 
14 (16%) 
74 (84%) 
66 (11%) 
516 (89%) 
0.220 
Smoking status Current 
Ex 
Never 
149 (22%) 
391 (68.5%) 
129 (22.5%) 
35 (40%) 
48 (54%) 
5 (6%) 
114 (20%) 
343  (59%) 
124 (21%) 
<0.001 
PPC, postoperative pulmonary complication; FEV1, forced vital capacity in 1 second; 178 
BMI, body mass index; ASA, American College of Anaesthetists; VATS, Video-assisted 179 
thoracoscopic surgery; PCA, patient controlled analgesia; COPD, chronic obstructive 180 
pulmonary disease; HTN, hypertension; IHD, ischaemic heart disease, NSLC, non-181 
small cell lung cancer. 182 
 183 
Using backward logistic regression to identify perioperative variables independently 184 
associated with PPCs our multivariate analysis included all variables. No significant 185 
interactions across any of the variables were found. Only COPD diagnosis and 186 
smoking status were associated with the development of a PPC (table 2). Patients 187 
who had COPD were 1.81 times more likely to develop PPC compared to non-COPD 188 
patients (95%CI 1.11–2.95; p=0.017). Current smokers were 5.42 times more likely to 189 
develop PPC that never smokers (95%CI 1.99-14.76; p<0.001), and ex-smokers were 190 
2.8 times more likely to develop PPC than never smokers (95%CI 1.08-7.28; p=0.035). 191 
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The goodness-of-fit test of this model remained non-significant during these steps 192 
with a p value very close to 1 showing a very good model fit (Hosmer and Lemeshow 193 
p=0.975). The overall predictive power of the model was 66.3% indicated by the area 194 
under the curve (ROC). The resulting logistic model had a sensitivity of 60.2% and 195 
specificity of 65.9% with the cut-off probability point set at 0.12. So in our model, a 196 
probability more than 0.12 means that a patients has 60.2% possibility to have a 197 
PPC. When the yielded probability is less than 0.12, patients have 65.9% chance to 198 
not develop PPC. The sensitivity of the model is the percentage of the group 199 
accurately identified by the model as having a PPC and the specificity is the 200 
percentage correctly identified as not having one. 201 
 202 
Table 2 Preoperative risk factors associated with PPC on multivariate analysis. 203 
Variables Estimate SE P-value OR 95% CI 
Constant -3.18 0.45 <0.001 - - 
COPD  0.59 0.25 0.017 1.81 1.11 - 2.95 
Current smoker (vs. never) 1.69 0.51 <0.001 5.42 1.99 - 14.76 
Ex smoker (vs. never) 1.03 0.49 0.035 2.80 1.08 - 7.28 
COPD, chronic obstructive pulmonary disease.   204 
 205 
Patients in the PPC group had a significantly longer (days) hospital LOS (12.7, 95%CI 206 
10.5-14.9 vs. 6.3, 95%CI 5.9-6.7; p<0.001), longer HDU LOS (4.2, 95%CI 3.4-4.9 vs. 1.9 207 
95%CI 1.8-2.1, p<0.001) and longer ITU LOS (2.1, 95%CI 1.0-3.3 vs. 0.2, 95%CI 0.1-0.4, 208 
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p<0.001). In the PPC group there were higher rates of ITU admissions (28% vs. 1.9%; 209 
p<0.001) (figure 1, table 3). The 30-day hospital readmission was higher in the PPC 210 
group (21% vs. 12%; p=0.023). Patients who developed a PPC in hospital had higher 211 
rate of readmission secondary to pneumonia and lower respiratory tract infections 212 
(9.1% vs. 3.8%; p=0.046).  213 
Of all patients there were 176 (26%) deaths with a median follow up of 12 months 214 
(95%CI 9.4-14.6). Causes of death included early postoperative complications (8.5%), 215 
cancer related deaths (65%), non-cancer related deaths (21%) and cause of death 216 
uncertain (5%). Patients with a PPC had a significantly higher 30-day (9% vs. 0.7%; 217 
p<0.001) and 90-day mortality (17% vs. 2.9%; p<0.001).  218 
 219 
Table 3 Morbidity and mortality following the development of a PPC.  220 
Variables PPC (n=88) Non-PPC 
(n=582) 
P-value 
Number of ITU admissions 25 (28%) 11 (1.9%) <0.001 
Mean LOS  
(95% CI) (days) 
Hospital 12.7 (10.5-14.9) 6.3 (5.9-6.7) <0.001 
HDU 4.2 (3.4-4.9) 1.9 (1.8-2.1) <0.001 
ITU 2.1 (1.0-3.3) 0.2 (0.1-0.4) <0.001 
Number of 30-
day hospital 
readmissions 
Total 18 (21%)  67 (12%) 0.023 
Pneumonia/LRTI 8 (9%) 22 (4%) 0.046 
Postoperative complication 10 (11%) 43 (7%) 0.198 
Uncertain 0 2 (0.3%) 0.754 
 14 
PPC, postoperative pulmonary complication; ITU, intensive treatment unit; LOS, 221 
length of stay; HDU, high dependency unit; LRTI, lower respiratory tract infection. 222 
 223 
Excluding patients who died of a postoperative complication (15/670, 2%), those 224 
who develop a PPC have a reduced OS with a mean follow up of 40 months (95%CI 225 
34.1-43.8 vs. 45.8, 95%CI 44.3-47.3; p=0.006) (figure 2). There were a significantly 226 
increased number of non-cancer related deaths in those who develop PPC (11 vs. 227 
5%; p=0.020), of which, non-cancer respiratory cause of death are more frequent in 228 
patients with a PPC. Significant independent risk factors for late deaths in patients 229 
with NSCLC were PPC (Cox regression: HR 2.00, 95%CI 1.19-3.20; p=0.005), cancer 230 
stage, age and 30-day readmission to hospital (table 4).  231 
Number of 
deaths 
 
Total 37 (42%) 139 (24%) <0.001 
30 day-mortality 8 (9%) 4 (0.7%) <0.001 
90 day-mortality 15 (17%) 16 (3%) <0.001 
Cause of death Postoperative complication 9 (10%) 6 (1%) <0.001 
Excluding postoperative 
complication 
28 (32%) 133 (22%) 0.017 
Cancer related 18 (20%) 97 (17%) 0.380 
Non-cancer 
related 
Total 10 (11%) 27 (5%) 0.020 
Respiratory 6 (6.8%) 13 (2.2%) 0.028 
Cardiovascular 3 (3.4%) 10 (1.7%) 0.395 
Other 1 (1.1%) 4 (0.7%) 0.507 
Uncertain 0 9 (1.5%) 0.615 
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 232 
Table 4 Significant Independent risk factors for late deaths in patients with non-small 233 
cell lung cancer. 234 
PPC, Postoperative pulmonary complication. 235 
 236 
DISCUSSION 237 
Our study has confirmed that PPCs are common in thoracic surgery. The short-term 238 
morbidity of developing a PPC following thoracic surgery is striking, with significantly 239 
longer hospital, ITU and HDU LOS, higher frequency of ITU admissions and higher 240 
frequency of hospital readmissions secondary to pulmonary infections. Furthermore, 241 
patients who develop a PPC have a significantly increased mortality, both in the early 242 
and late stages following surgery. After excluding immediate post-operative deaths, 243 
developing a PPC is a significant independent risk factor for late deaths and these 244 
patients have a worse long-term survival. Furthermore we observed a high rate of 245 
non-cancer related deaths in this cohort.   246 
The frequency of PPCs observed at this regional thoracic surgery unit (13%) is 247 
Variables Estimate SE P-value HR 95% CI 
PPC  0.69 0.25 0.006 2.00 1.19 – 3.20 
Staging IIA/B  1.07 0.22 <0.001 2.92 1.89 – 4.56 
Staging IIIA 1.28 0.25 <0.001 3.60 2.20 – 5.85 
Staging IIIB 1.91 0.61 0.002 6.72 1.61 –18.90 
Age 0.03 0.01 0.003 1.04 1.01 - 1.06 
Readmission (30-days)  0.62 0.23 0.008 1.86 1.15- 2.89 
 16 
concurrent with other studies [10-15]. The incidence of PPC following thoracic 248 
surgery ranges between studies predominantly because there is no standard; it is 249 
dependent on the type of complications included, the definition of pulmonary 250 
complications, and the type of surgery. Use of the objective MGS to define PPC does 251 
not include rare but serious postoperative complications such as broncho-pleural 252 
fistulas, which required re-operation in 0.4% of our patients, and also pulmonary 253 
embolism, which has been described in 2% of patients after thoracic surgery [16]. 254 
However, the fact that those more frequent, and probably less severe PPCs detected 255 
by the MGS were still associated with a higher short and long-term mortality rate is 256 
an important message.  257 
Patients who develop a PPC are more than twice as likely to be readmitted within 258 
30-days of surgery, and nearly 3 times more likely to re-present with respiratory 259 
tract infections. Hospital readmission is not only a serious morbidity; we 260 
demonstrate it also to be an independent risk factor for the late deaths observed in 261 
our study. Patients who are readmitted within 30-days of lung cancer surgery have 262 
been shown to have a 6-fold increase in 90-day postoperative mortality [17]. In our 263 
study the 90-day mortality was 2.6 times that of 30-day mortality, compatible with 264 
other study findings [9, 18]. Thus, this increased mortality following thoracic surgery 265 
is not explained by immediate postoperative deaths alone; we hypothesised that 266 
PPCs have a role in these later deaths observed. 267 
Our study has shown that PPCs are significantly associated with reduced OS 268 
following thoracic surgery for lung resection.  There is a paucity of data on the 269 
impact of PPCs on long-term outcome in thoracic surgery. A retrospective study 270 
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which included patients aged 66-80 who have undergone a lobectomy for stage 1 271 
NSCLC found that development of a PPC was associated with reduced 5-year OS 272 
(52.7 vs. 65.9%, p<0.001) and was an independent risk factor for mortality (HR 1.46, 273 
95% CI, 1.24-1.73) [19]. We have also shown that developing a PPC is a independent 274 
risk factor for late deaths, but in comparison our study is not limited by any inclusion 275 
criteria other than national guidelines [6]. Therefore we have included those patients 276 
who are older and have more advanced staging of cancer, which we and other 277 
authors have found to be additional independent risk factors for late deaths [20, 21].  278 
We demonstrate for the first time that after excluding immediate postoperative 279 
deaths, patients with a PPC are more likely to die of late non-cancer related deaths. 280 
This compares to the outcome of patients who are admitted to hospital secondary to 281 
community acquired pneumonia (CAP), these patients have an increased risk of 282 
subsequent pneumonia and mortality after discharge, and a substantial proportion 283 
of these deaths are due to non-malignant respiratory disease [22]. Some of the late 284 
deaths in patients who developed a PPC were secondary to cardiovascular disease, 285 
indeed there is increasing evidence that pneumonia is associated with increased risk 286 
of cardiovascular complications, which may be due to residual inflammation having a 287 
role in triggering procoagulant pathways in these individuals [23].  288 
COPD and current smoking were found to be independent risk factors in the 289 
development of PPCs in ours and other studies [10, 21]. Our multivariate model for 290 
assessing of risk factors has a c-index of 0.66 therefore it cannot be used as a 291 
diagnostic/highly predictive tool as we would like a predictive power ideally more 292 
than 80-90%. Nevertheless, our analysis identified factors having significant 293 
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association with PPC. Those patients diagnosed with COPD have increased risk of 294 
both pneumonia and atelectasis after surgery [24, 25]. We found on univariate 295 
analysis that a lower preoperative FEV1 percentage predicted was associated with 296 
the development of a PPC, though on multivariate analysis, FEV1 is not an 297 
independent risk factor, as previously shown [10]. In our study carbon monoxide 298 
lung diffusion capacity (DLCO) was performed only in patients with limited exercise 299 
tolerance or lung volumes so data are limited. However, studies have shown DLCO 300 
not to be an independent risk factor for long-term survival following thoracic surgery 301 
for lung cancer [26, 27]. Risk modification for patients with COPD would be through 302 
a pulmonary rehabilitation programme [28], which in thoracic surgery has shown 303 
encouraging results in reducing PPCs [29], but more robust studies are needed in this 304 
field.  305 
Smoking is the biggest independent risk factor for developing PPCs; indeed our study 306 
has shown PPCs to be up to five times more common in current smokers when 307 
compared to never smokers, similar to other study findings [30]. Key mechanisms 308 
are likely to involve the effect smoking has on impairing the mucociliary escalator 309 
[31], and also both the antimicrobial and pro-inflammatory functions of alveolar 310 
macrophages, which decreases further during anaesthesia and surgery [32]. Risk 311 
modification would be in the form of smoking cessation; however the duration 312 
needed in order to reduce postoperative risk remains a debated topic and is a much-313 
needed area of future research.  314 
Independent risk factors for developing PPCs have previously been identified as 315 
smoking, advanced age (≥75 year old), reduced mobility, ASA ≥3, cardiovascular 316 
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comorbidity, COPD and BMI >/ 30kg/m2 [10-14]. Interestingly BMI, age and ASA were 317 
not significant risk factors for the development of PPCs in our study. Other 318 
investigators have found that obesity does not confer greater morbidity and 319 
mortality after lung resection [33]. We have shown that age is not a predictive factor 320 
for development of PPC which we believe is an important finding for the clinical 321 
community and is supported by other studies showing no significant difference in 322 
postoperative complications in patients over the age of 75 [21, 34].  323 
Study strengths and limitations 324 
This is a real-life study involving consecutive patients undergoing thoracic surgery in 325 
a tertiary centre; our patient demographics and staging of cancer is comparable to 326 
national data [9]. The main limitation of our study is the low number of VATS cases 327 
recorded. VATS lobectomy has since increased to 1/3 of all lobectomies carried out 328 
in the UK due to the perceived minimally invasive nature of the procedure with 329 
reduced complications. Indeed we have previously described that the PPC incidence 330 
in VATS cases seems to be lower [35]. The data of this study precedes the growth of 331 
VATS lobectomies, therefore the majority of our lung resections over the time frame 332 
were done via thoracotomy, within in the latter half of the study 2 of the 5 surgeons 333 
had started to perform an increasing number of VATS lobectomies (35%), compared 334 
to the first half of the study period (3.4%). The finding of VATS approach not to show 335 
a significant reduction in incidence of PPC is most likely because of under powering. 336 
Further studies into the effects of transition of thoracotomy to VATS on PPC 337 
frequency and long-term outcome will need to be conducted. There is limitation 338 
with regards to the patient follow up data; as information on mortality and cause of 339 
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death were obtained from hospital records and death certificates in a retrospective 340 
manner, in a few patients cause of death could not be ascertained (5%). Additionally, 341 
we did not follow up for cancer recurrence and therefore could not assess the effect 342 
of PPC on disease free survival in patients with lung cancer, which would be an 343 
interesting area for further investigation. 344 
 345 
CONCLUSION 346 
In summary, developing a PPC after thoracic surgery is associated with a poorer 347 
long-term outcome. We have found COPD and smoking are independent risk factors 348 
for developing PPCs, whilst age was not a predictive factor. Further research is 349 
required into the effect of risk modification on the development of PPCs and 350 
subsequent long-term outcome following thoracic surgery. 351 
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FIGURE LEGENDS 459 
 460 
Figure 1 Effect of PPC on hospital length of stay (days). PPC, postoperative 461 
pulmonary complication; LOS, Length of stay; ITU, Intensive treatment unit; HDU 462 
High dependency unit, TOTAL; Total length of hospital stay. 463 
 464 
Figure 2 Overall survival of patients with and without a PPC excluding early 465 
postoperative deaths. PPC, Postoperative pulmonary complication; Black line: no 466 
PPC, Grey line: PPC. 467 
